amlodipine has been researched along with Thalassemias in 4 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 9.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| " Amlodipine, L-type calcium channel blocker with regular chelation therapy may reduce myocardial iron overload." | 5.51 | Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial. ( Aggarwal, P; Agrawal, V; Gupta, V; Kumar, I; Raj, V, 2022) |
| "Our meta-analysis found that amlodipine significantly increases cardiac T2* and decreases MIC, hence decreasing the incidence of cardiomyopathy-related iron overload in thalassemia patients." | 5.41 | Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis. ( Abdelaziz, A; Abdelwahab, OA; Amer, BE; Badawy, MM; Diab, RA; Elsharkawy, A; Goudy, YM; Mouffokes, A; Soliman, Y, 2023) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 5.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, V | 1 |
| Kumar, I | 1 |
| Raj, V | 1 |
| Aggarwal, P | 1 |
| Agrawal, V | 1 |
| Soliman, Y | 1 |
| Abdelaziz, A | 1 |
| Mouffokes, A | 1 |
| Amer, BE | 1 |
| Goudy, YM | 1 |
| Abdelwahab, OA | 1 |
| Badawy, MM | 1 |
| Diab, RA | 1 |
| Elsharkawy, A | 1 |
| Elfaituri, MK | 1 |
| Ghozy, S | 1 |
| Ebied, A | 1 |
| Morra, ME | 1 |
| Hassan, OG | 1 |
| Alhusseiny, A | 1 |
| Abbas, AS | 1 |
| Sherif, NA | 1 |
| Fernandes, JL | 1 |
| Huy, NT | 1 |
| Shakoor, A | 1 |
| Zahoor, M | 1 |
| Sadaf, A | 1 |
| Alvi, N | 1 |
| Fadoo, Z | 1 |
| Rizvi, A | 1 |
| Quadri, F | 1 |
| Tipoo, FA | 1 |
| Khurshid, M | 1 |
| Sajjad, Z | 1 |
| Colan, S | 1 |
| Hasan, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study[NCT02065492] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Thalassemias
| Article | Year |
|---|---|
Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Humans; Iron; Iron Chelating Agents; Iron Ov | 2023 |
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Topics: Amlodipine; beta-Thalassemia; Humans; Iron Chelating Agents; Iron Overload; Thalassemia | 2021 |
2 trials available for amlodipine and Thalassemias
| Article | Year |
|---|---|
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Chelation Therapy; Child; Ferritins; Humans; | 2022 |
Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
Topics: Adolescent; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiomyopathies; Chelat | 2014 |